Cerebrospinal fluid biomarkers for Alzheimer's disease: Diagnostic performance in a homogeneous mono-center population

Journal of Alzheimer's Disease

Volumn 24, Issue 3, 2011, Pages 537-546

  Johansson, Per ^a,b   Mattsson, Niklas ^b   Hansson, Oskar ^c   Wallin, Anders ^b   Johansson, Jan Ove ^b   Andreasson, Ulf ^b   Zetterberg, Henrik ^b   Blennow, Kaj ^b   Svensson, Johan ^b,d,e  

^a SKARABORG HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d SKARABORG HOSPITAL   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; amyloid; biomarkers; cerebrospinal fluid; diagnosis

Indexed keywords

AMYLOID BETA PRECURSOR PROTEIN ALPHA; AMYLOID BETA PRECURSOR PROTEIN BETA; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN X-38; AMYLOID BETA PROTEIN X-40; AMYLOID BETA PROTEIN X-42; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; PROTEIN P TAU; PROTEIN T TAU; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; WAIST HIP RATIO;

EID: 79957854917     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-101878     Document Type: Article

References (37)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimers disease. Lancet 368, 387-403.
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117. (Pubitemid 41797645)
3. Hardy JA, Higgins GA (1992) Alzheimers disease: the amyloid cascade hypothesis. Science 256, 184-185.
4. Selkoe DJ (1991) The molecular pathology of Alzheimers disease. Neuron 6, 487-498.
5. Andreasson U, Portelius E, Andersson ME, Blennow K, Zetterberg H (2007) Aspects of beta-amyloid as a biomarker for Alzheimers disease. Biomarkers Med 1, 59-78.
6. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimers disease. Lancet Neurol 2, 605-613. (Pubitemid 37162569)
7. Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652-656. (Pubitemid 36246085)
8. Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimers disease. NeuroRx 1, 213-225. (Pubitemid 46589353)
9. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N(2007) Longitudinal stability of CSF biomarkers in Alzheimers disease. Neurosci Lett 419, 18-22. (Pubitemid 46694097)
10. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A (2007) Intra-individual stability of CSF biomarkers for Alzheimers disease over two years. J Alzheimers Dis 12, 255-260. (Pubitemid 350179256)
11. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimers disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228-234. (Pubitemid 43238346)
12. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
13. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund L-O, Freund-Levi Y, Tsolaki M, Minthon L, Wallin A K, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimers disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPAstudy: a prospective cohort study. Lancet Neurol 8, 619-627.
14. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
15. Royall DR, Cordes JA, Polk M (1998) CLOX: an executive clock drawing task. J Neurol Neurosurg Psychiatry 64, 588-594. (Pubitemid 28204143)
16. Buchhave P, Stomrud E, Warkentin S, Blennow K, Minthon L, Hansson O (2008) Cube copying test in combination with rCBF or CSF A beta 42 predicts development of Alzheimers disease. Dement Geriatr Cogn Disord 25, 544-552. (Pubitemid 351957418)
17. Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC (1991) The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol 48, 725-728.
18. Yesavage JA (1988) Geriatric depression scale. Psychopharmacol Bull 24, 709-711.
19. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th ed., American Psychiatric Association. Washington, DC.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 34, 939-944. (Pubitemid 14076461)
21. PetersenRC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194. (Pubitemid 39222988)
22. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, Moody M, OBrien M, Yamaguchi T, Grafman J, Drayer B, Bennett D, Fisher M, Ogata J, Kokmen E, Bermejo F, Wolf P, Gorelick P, Bick K, Pajeau A, Bell M, DeCarli C, Culebras A, Korczyn A, Bogousslavsky J, Hartmann A, Scheinberg P (1993)Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260. (Pubitemid 23060253)
23. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW (2000) Research criteria for subcortical vascular dementia in clinical trials. Neural Transm Suppl 59, 23-30. (Pubitemid 30479402)
24. McKeith IG (2006) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 9, 417-423. (Pubitemid 44253336)
25. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51, 1546-1554.
26. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245-258.
27. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K (2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65, 1102-1107.
28. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245. (Pubitemid 26002016)
29. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52. (Pubitemid 30224621)
30. Bylesjö M, Rantalainen M, Cloarec O, Nicholson J, Holmes E, Trygg J (2007) OPLS discriminant analysis: combining the strengths of PLS-DAand SIMCA classification. J Chemometrics 20, 341-351.
31. Eastment H, Krzanowski W (1982) Crossvalidatory choice of the number of components from a principal component analysis. Technometrics 24, 73-77. (Pubitemid 12475882)
32. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC (2001) Practice parameter: diagnosis of dementia (an evidencebased review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1143-1153. (Pubitemid 32405708)
33. Jellinger K, Danielczyk W, Fischer P, Gabriel E (1990) Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci 95, 239-258. (Pubitemid 20097713)
34. JellingerKA(2006) Clinicopathological analysis of dementia disorders in the elderly-an update. J Alzheimers Dis 9, 61-70. (Pubitemid 44253299)
35. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimers disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
36. Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S (2009) Improved discrimination of autopsyconfirmed Alzheimers disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int 55, 214-218.
37. Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E (2005) Amino-truncated-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 51, 1650-1660.